Alkermes Public Limited Company, an integrated biopharmaceutical
company, develops medicines that enhance patient outcomes. The company
offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA
SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple
sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and
opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower
cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to
severe pain; EMEND to treat nausea associated with chemotherapy and
surgery; and FOCALIN XR and RITALIN LA for attention deficit and
hyperactivity disorder.
Please take a look at the 1-year chart of ALKS (Alkermes Public Limited Company) below with my added notations:
After rallying all the way into February, ALKS cooled off a bit in
March. During the last 3 months the stock has created a clear resistance
level at $48, while also forming an up-trending level of support as
well. At some point the stock has to break one of those levels.
The Tale of the Tape: ALKS is wedged between two
levels. A short trade could be made on a break of the trendline with a
stop placed above the entry. However, if the stock were to break above
the $48 resistance traders might want to look to get long on the stock
instead.
Please share this article
No comments:
Post a Comment